The Burrill Report

The Burrill Report (October 7, 2013): Funding a Personalized Immunotherapy for MS (.MP3,23.53 Mb)


Opexa Therapeutics, which is in mid-stage clinical testing for its personalized immunotherapy for the treatment of secondary progressive multiple sclerosis, has been busy over the past year. The company has completed a number of financings to fund its ongoing clinical trial and entered into a licensing agreement with Merck Serono for its lead therapeutic Tcelna. We spoke to Neil Warma, president and CEO of Opexa, about Tcelna, possible other indications for the experimental therapy beyond MS, and what the environment today is like for smaller biotechs raising money.

October 03, 2013
http://www.burrillreport.com/article-funding_a_personalized_immunotherapy_for_ms.html